Using advanced wound care and hyperbaric oxygen to manage wound complications following treatment of vulvovaginal carcinoma.

Postoperative management of patients with vulvar cancer is associated with a high incidence of poor wound healing and radiation -induced late tissue necrosis. This case series demonstrates the impact on wound healing with the use of hyperbaric oxygen therapy and advanced wound care following radical vulvectomy and/or radiation therapy. A retrospective case series was performed of all patients from 2016 to 2017 with lower genital cancer who underwent radical surgery with or without chemoradiation treatment, experienced wound dehiscence or late tissue radionecrosis, and were treated with advanced wound care, including hyperbaric oxygen therapy (HBO). Five patients were included with a mean age of 63; four had squamous cell carcinoma and one patient had vaginal adenocarcinoma secondary to prior diethylstilbestrol exposure. Three patients underwent radical vulvectomy. All received pelvic radiation therapy, subsequently experienced wound complications, and were managed with advanced wound care and HBO. The mean reduction in wound area at the final wound follow up visit after completion of HBO therapy was found to be 76%, ranging 42-95%, with an average follow up of five months. The mean number of HBO sessions per patient was 58. Complete tissue granulation or significant improvement in tissue radionecrosis was present in all patients. Advanced wound care and hyperbaric oxygen therapy are beneficial in the management of postoperative wound complications. Prospective studies are needed to identify the optimal use of perioperative hyperbaric oxygen and appropriate wound care for patients with gynecologic malignancies.

Appropriateness of newborn screening for α1-antitrypsin deficiency.

OBJECTIVE: The Alpha-1 Foundation convened a workshop to consider the appropriateness of newborn screening for α-1-antitrypsin (AAT) deficiency. METHODS: A review of natural history and technical data was conducted. RESULTS: Homozygous ZZ AAT deficiency is a common genetic disease occurring in 1 in 2000 to 3500 births; however, it is underrecognized and most patients are undiagnosed. AAT deficiency can cause chronic liver disease, cirrhosis, and liver failure in children and adults, and lung disease in adults. The clinical course is highly variable. Some neonates present with cholestatic hepatitis and some children require liver transplantation, but many patients remain well into adulthood. Some adults develop emphysema. There is no treatment for AAT liver disease, other than supportive care and liver transplant. There are no data on the effect of early diagnosis on liver disease. Avoidance of smoking is of proven benefit to reduce future lung disease, as is protein replacement therapy. Justifying newborn screening with the aim of reducing smoking and reducing adult lung disease-years in the future would be a significant paradigm shift for the screening field. Recent passage of the Genetic Information Nondiscrimination Act (GINA) and the Affordable Care Act may have a major effect on reducing the psychosocial and financial risks of newborn screening because many asymptomatic children would be identified. Data on the risk-benefit ratio of screening in the new legal climate are lacking. CONCLUSIONS: Workshop participants recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening.

Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits?

OBJECTIVE: Passive scattering proton beam (PSPB) radiotherapy for accelerated partial-breast irradiation (APBI) provides superior dosimetry for APBI three-dimensional conformal photon radiotherapy (3DCRT). Here we examine the potential incremental benefit of intensity-modulated proton radiotherapy (IMPT) for APBI and compare its dosimetry with PSPB and 3DCRT. METHODS: Two theoretical IMPT plans, TANGENT_PAIR and TANGENT_ENFACE, were created for 11 patients previously treated with 3DCRT APBI and were compared with PSPB and 3DCRT plans for the same CT data sets. The impact of range, motion and set-up uncertainties as well as scanned spot mismatching between fields of IMPT plans was evaluated. RESULTS: IMPT plans for APBI were significantly better regarding breast skin sparing (p<0.005) and other normal tissue sparing than 3DCRT plans (p<0.01) with comparable target coverage (p=ns). IMPT plans were statistically better than PSPB plans regarding breast skin (p<0.002) and non-target breast (p<0.007) in higher dose regions but worse or comparable in lower dose regions. IMPT plans using TANGENT_ENFACE were superior to that using TANGENT_PAIR in terms of target coverage (p<0.003) and normal tissue sparing (p<0.05) in low-dose regions. IMPT uncertainties were demonstrated for multiple causes. Qualitative comparison of dose-volume histogram confidence intervals for IMPT suggests that numeric gains may be offset by IMPT uncertainties. CONCLUSION: Using current clinical dosimetry, PSPB provides excellent dosimetry compared with 3DCRT with fewer uncertainties compared with IMPT. ADVANCES IN KNOWLEDGE: As currently delivered in the clinic, PSPB planning for APBI provides as good or better dosimetry than IMPT with less uncertainty.

The predicted relative risk of premature ovarian failure for three radiotherapy modalities in a girl receiving craniospinal irradiation.

In girls and young women, irradiation of the ovaries can reduce the number of viable ovarian primordial follicles, which may lead to premature ovarian failure (POF) and subsequently to sterility. One strategy to minimize this late effect is to reduce the radiation dose to the ovaries. A primary means of reducing dose is to choose a radiotherapy technique that avoids irradiating nearby normal tissue; however, the relative risk of POF (RRPOF) due to the various therapeutic options has not been assessed. This study compared the predicted RRPOF after craniospinal proton radiotherapy, conventional photon radiotherapy (CRT) and intensity-modulated photon radiotherapy (IMRT). We calculated the equivalent dose delivered to the ovaries of an 11-year-old girl from therapeutic and stray radiation. We then predicted the percentage of ovarian primordial follicles killed by radiation and used this as a measure of the RRPOF; we also calculated the ratio of the relative risk of POF (RRRPOF) among the three radiotherapies. Proton radiotherapy had a lower RRPOF than either of the other two types. We also tested the sensitivity of the RRRPOF between photon and proton therapies to the anatomic position of the ovaries, i.e., proximity to the treatment field (2 ≤ RRRPOF ≤ 10). We found that CRT and IMRT have higher risks of POF than passive-scattering proton radiotherapy (PRT) does, regardless of uncertainties in the ovarian location. Overall, PRT represents a lower RRPOF over the two other modalities.

SU-E-T-257: Risk of Radiogenic Second Cancer after Photon and Proton Craniospinal Irradiation.

PURPOSE: To compare proton and photon therapies in terms of the risks of second cancers for a pediatric medulloblastoma patient receiving craniospinal irradiation (CSI). METHODS: Two CSI treatment plans with 23.4 Gy or Gy (RBE) prescribed dose were computed for a 4-year-old boy withmedulloblastoma: a three-field 6-MV photon therapy plan and a four-field proton therapy plan. The primary doses for both plans were determined using a commercial treatment planning system. Stray radiation doses for proton therapy were determined from Monte Carlo simulations, and stray radiation doses for photon therapy were determined from measured data. The dose-risk model based on Biological Effects of Ionization Radiation VII report was used to estimate risk of second cancer. RESULTS: Baseline predictions of the relative risk of each organ were always less for proton CSI than for photon CSI after various follow-up years for the patient. The lifetime risks of the incidence of second cancer after proton CSI and photon CSI were 7.7% and 92%, respectively, and the ratio of lifetime risk was 0.083. Uncertainty analysis revealed the qualitative findings of this study were insensitive to any plausible changes of dose-risk models and mean neutron radiation weighting factor. CONCLUSIONS: Proton therapy confers lower predicted risk of second cancer for the pediatric medulloblastoma patient compared with photon therapy.

SU-E-T-447: Evaluation of the Anisotropic Analytical Algorithm (AAA) Heterogeneity Correction Dose Calculation in Flattened and Flattening- Filter-Free (FFF) Beams for High Energy X-Ray Beams Using the Radiological Physics Center (RPC) Lung Phantom.

PURPOSE: Compare the accuracy of AAA heterogeneity corrected dose calculation algorithm for high energy x-ray beams (>10 MV) for flattened and FFF beams using RPC anthropomorphic thorax phantom. METHODS: Six static beam SBRT treatment plans were created using the Varian Eclipse treatment planning system (TPS) AAA v.8.9.08 heterogeneity correction algorithm. Two flattened beam plans (6 MV and 18 MV) and four other plans (6 MV, 6 MV FFF, 10 MV FFF and 15 MV) were delivered using a Clinac 21EX and TrueBeam STx, respectively. Prescription dose/coverage, 6 Gy to 95% PTV, and constraints were the same for all plans. The phantom contained radiochromic films in the 3 major planes and TLDs in the heart, spine, and tumor. Point doses and 2D dose distributions were exported from the Eclipse TPS and compared with the measured doses. The gamma index analysis evaluation criteria of ±5% dose to agreement and 3 mm distance to agreement was used. RESULTS: TLD to TPS tumor point dose ratios were 0.971±0.006(6MV) and 0.957±0.002(6MV), 0.995±0.005(15MV), 1.114±0.006(18MV), and 0.957±0.003(6MV FFF), 0.974±0.011(10MV FFF) for the six plans. Using ±5%/3mm gamma analysis criteria, the average passing rates for all three films were 96.3% and 95.5%, 97.4%, 66.1%, 93.7%, and 96.3% for the 6 MV, 6 MV, 15 MV, 18 MV, 6 MV FFF, and 10 MV FFF plans, respectively. Dose profiles were also evaluated. CONCLUSIONS: The current RPC credentialing criteria are: RPC/Inst. tumor dose ratio of 0.97±0.05 and 85% of the pixels in each film plane must pass a ±5%/5mm gamma index analysis. These data demonstrate that the AAA heterogeneity correction dose calculation algorithm is accurate for photon energies in 6-15 MV range for flattened and FFF beams. Heterogeneity corrected dose calculations for photon energies >15 MV were not accurate. Work supported by grants CA10953 and CA81647 (NCI, DHHS).

SU-E-T-528: Appraisal of Acorus XB and Convolution Dose Algorithms in Field Junction of Breast Tangential/superclavicular Fields.

PURPOSE: Dose accuracy injunction regions of breast-tangential therapy is a challenge, and inaccurate dose predictions may lead to unreal hot/cold spots. Availability of the novel deterministic radiation transport method Acuros XB (AXB) provides a potential for more accurate dose predictions. This study assesses relative dose accuracies of this and the widely used other algorithms: collapsed cone convolution (CCC) and anisotropic analytical algorithm (AAA) against film measurements. METHODS: A typical tangential and superclav fileld combination was planned for an anthropomorphic body phantom using Pinnacle-9.0 treatment-planning system (TPS). The created plan employing 6MV beam was delivered to the phantom on a Varian linac. In region of the field junction of tangentials & superclav, films (EBT2) were placed in coronal planes at two depths (∼ 2 and 4 cm). Optical density was measured along and ± 5mm away from the field-match line, and converted to dose using film-calibration curve specific to the batch of film. The same plan was also imported to Eclipse TPS using an import filter written in MATLAB. Algorithms Pinnacle CCC 9.0, Eclipse AAA 10.0.24 and AXB 11.0.3 were used for calculations. Comparison of the measured doses (assumed as gold standard) against doses calculated from planning-systems were preformed in a MATLAB platform. RESULTS: In general, dose distributions from all three TPS algorithms are found to agree closely with film data. Agreements between AXB and CCC dose calculations were found to be reasonable. AXB appears to be better in modeling the backscatter effects in the heterogeneous regions. AAA calculations gives acceptable results, but with less accuracy compared to CCC and AXB. CONCLUSIONS: The novel deterministic algorithm AXB in Eclipse is found to provide better agreement with measured data in breast-tangential therapy. Benefits of using Acuors XB algorithm in tangential fields planning requires further investigation. This work was funded by National Institutes of Health through grant 2R44CA105806-02 and MD Anderson’s Cancer Center Support Grant CA0 16672.

SU-E-T-519: Experimental Evaluation of Deterministic Acuros XB Radiation Transport Algorithm for Heterogeneity Dose Calculation Using the Radiological Physics Center's Lung Phantom.

PURPOSE: To evaluate the heterogeneity corrected dose calculations from the Acuros XB (AXB), a novel deterministic dose calculation algorithm based on grid-based Boltzmann transport equation solver (GBBS), for IMRT and VMAT plans. METHODS: The Radiological Physics Center's lung phantom was used to create clinically equivalent IMRT and VMAT plans (RapidArc) with the Eclipse planning system 10.0 that were delivered using a Varian 23 iX. Absolute doses and relative dose distributions were measured with thermoluminescent dosimeters (TLDs) and radiochromic film. The measured dose distributions were compared with calculated doses from both AXB (11.0.3) and AAA (10.0.24) dose calculation algorithms. The AXB calculated dose-to-water and dose-to-medium were both compared to measurements. Gamma analysis (±7%/4mm, ±5%/3mm, and ±3%/3mm) was used to quantify correspondence between AXB dose distributions and the film measurements. The computation time between AAA and AXB were also evaluated. RESULTS: For TLD point doses, both AAA and AXB heterogeneity corrected dose calculations are within 5% inside the PTV for both IMRT and VMAT plans. The agreements observed between the measured and calculated doses for both AXB dose reporting methods are better than those observed with the AAA algorithm. The gamma analysis showed that the differences between AAA, AXB and film measurement met the RPC ±7%/4 mm criteria. The percent of pixels passing rate for both the AXB dose to medium and AXB dose to water are higher than AAA. The computation time between AAA and AXB are comparable for IMRT plans but AXB is significantly faster (4 times) than AAA for VMAT plans. CONCLUSIONS: The AXB implemented in the Eclipse planning system calculates a more accurate heterogeneity corrected dose than the AAA algorithm as compared to measurement in lung and improve the calculation speed for VMAT radiotherapy. Work supported by grants CA10953, CA81647, 2R44CA105806-02, CA016672 (NCI, DHHS).

WE-G-213CD-01: 4D Optimization for Scanned Ion Beam Tracking Therapy for Moving Tumors.

PURPOSE: To apply scanned ion radiotherapy to patients with moving tumors, motion mitigation approaches are needed. The purpose of the current study was to determine whether 4D optimized ion beam tracking therapy could reduce dose to critical structures near a moving target while maintaining target dose coverage. METHODS: A conjugate gradient minimization algorithm was developed to incorporate 4D organ motion data in the optimization of scanned ion pencil beam fluences. Treatment plans for 3D and 4D optimized carbon beam tracking were prepared using an in- house code for a sphere target volume moving in water with a proximal avoidance volume. For 1 lung cancer patient, 3D and 4D optimized carbon beam tracking treatment plans were designed to provide uniform dose coverage to a clinical target volume and minimal dose to the heart. For both the water phantom and patient case, 4D dose distributions were calculated. Differences between 3D and 4D optimized beam tracking were analyzed using dose colorplanes, dose-volume histograms, and dose-volume statistics. RESULTS: For the sphere target, 3D optimized beam tracking achieved target dose coverage of (100.0 ± 0.3)% and a mean and maximum avoidance volume dose of 26.1% and 89.4%, respectively. 4D optimized beam tracking achieved target dose coverage of (99.9 ± 0.4)% and a mean and maximum avoidance volume dose of 7.7% and 42.2%, respectively. For the lung patient, 3D optimized beam tracking achieved target dose coverage of (101.0 ± 5.9)% and a mean and maximum heart dose of 7.7%and 103.4%, respectively. 4D optimized beam tracking achieved target dose coverage of (100.0 ± 0.1)% and a mean and maximum heart dose of 8.7% and 100.3%, respectively. CONCLUSIONS: 4D optimized ion beam tracking therapy may be used to reduce the maximum dose to critical structures near a moving target, compared to 3D optimized ion beam tracking therapy. Work supported by the Rosalie B. Hite Fellowship, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Poster - Thur Eve - 36: Out-of-Field dose in craniospinal irradiation.

The risk of radiotherapy induced secondary cancer depends on the integral dose delivered to the patient where the dose delivered within the radiation field is accounted for, as well as dose to out-of-field organs from scattered and leakage radiation. While commercial treatment planning systems allow accurate determination of in-field dose, they are generally not capable of accurate out-of-field dose prediction. Secondary cancer risk is especially an issue in craniospinal treatments where involved patients are often children or young adults. In this work we therefore propose a mathematical model that accurately predicts out-of-field dose for patients treated by craniospinal irradiation at the American University of Beirut Medical Center. An anthropomorphic phantom was imaged, planned and treated, with thermoluminescent dosimeters inserted in the phantom at in-field and out-of-field locations. The measurements showed that our treatment planning system calculated accurately (within 2%) dose inside the field, but did not perform well at points just outside the field edge and consistently underestimated the dose at points further away from the field edge. From the out-of-field measured data, a model was developed that predicts out-of-field dose at a point in the patient based on the distance of that point to the treatment field edge. The developed model is of the double-gaussian type; it contains parameters that can be tuned to make it applicable in other centers where linac geometry and treatment techniques may differ.

Qualitative assessment of the emotional and behavioural responses of haemophilia A carriers to negative experiences in their medical care.

Previous discussions with haemophilia A (HA) carriers suggested that carriers may experience inappropriate care, resulting in poor relationships with healthcare providers (HCPs; principally physicians and nurses), and unfortunate and extreme emotional and behavioural responses. This was a qualitative study to explore medical experiences of HA carriers and their emotional and behavioural responses. Eleven HA carriers and five Haemophilia Treatment Centre nurses were interviewed. Themes were identified using QSR NVivo 8.0. Carriers and nurses reported HA-related bleeding symptoms in carriers, including life-threatening haemorrhage following injury or medical intervention. Menorrhagia was common and distressing. Negative carrier experiences were related in the determination of genotypic and phenotypic status, management, precautions and HCP attitude, including dismissing carriers' symptoms, concerns or requests for care. Carriers responded with mistrust, lost confidence, disappointment, fear, anxiety, doubt of self or child, discussing experiences, avoidance of healthcare and self-treatment. Dismissive HCP attitudes, ignorance about bleeding disorders in women and unique aspects of the carrier population appear to make errors more likely. This study indicates that carriers experience inappropriate care and encounter dismissive attitudes, and respond emotionally and behaviourally. Our model suggests that systematic medical errors aggravate a negative feedback loop leading to negative emotional and behavioural responses and worsening carrier care. Improved carrier care policies and increased awareness of women's bleeding disorders may improve this situation. Further research is needed to determine whether the themes identified in this study accurately reflect the experiences of carriers in general.

Paratesticular paraganglioma: a rare cause of an intrascrotal mass.

We describe a case of a paratesticular paraganglioma in a 33-year-old man who presented with a scrotal mass and underwent a right testicular exploration. Metastasis is the only definite criterion for diagnosis of a malignant paraganglioma; however, lymphovascular invasion was noted in this case, which warranted a close clinical surveillance. The patient is currently well with no evidence of disease 18 months after radical orchiectomy. Paratesticular paragangliomas are extremely rare tumors with 6 cases reported in English literature. The histogenesis of these tumors is unknown. Though the histology and immunohistochemistry resemble those of paragangliomas at any other location, these tumors raise a plethora of differential diagnoses especially with the more commonly occurring tumors. Herein the relevant histopathologic differential diagnoses are discussed along with a brief review of literature.

Total hip arthroplasty in the underweight.

The outcomes of 20 patients diagnosed with osteoarthritis or rheumatoid arthritis with body mass index less than 18.5 (considered underweight) who received total hip arthroplasty at a single institution were reviewed. Surgical complications in the first 30 days after surgery included 1 prolonged surgical site drainage and 3 posterior dislocations. Two patients experienced medical complications that included hematemesis, confusion, aspiration pneumonia, and death. Sixty-five percent of the patients received at least one blood transfusion. Harris hip scores improved from 35 to 81 (P < .05) at an average of 6.1 years (2-10.1 years) of follow-up. Total hip arthroplasty is effective in patients who are underweight; however, they appear to be at an increased risk of dislocation and blood transfusion.

Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice.

PURPOSE: Currently there is no satisfactory treatment for metastatic melanoma. Radioimmunotherapy (RIT) uses the antigen-antibody interaction to deliver lethal radiation to target cells. Recently we established the feasibility of targeting melanin in tumors with 188-Rhenium ((188)Re)-labeled 6D2 mAb to melanin. Here we carried out pre-clinical development of (188)Re-6D2 to accrue information necessary for a Phase I trial in patients with metastatic melanoma. RESULTS: TCEP proved to be effective in generating a sufficient number of -SH groups on 6D2 to ensure high radiolabeling yields with (188)Re and preserved its structural integrity. (188)Re-6D2 was quickly cleared from the blood with the half-life of approximately 5 hrs and from the body--with the half-life of 10 hr. The doses of 0.5, 1.0 and 1.5 mCi significantly (p < 0.05) slowed down A2058 tumor growth in nude mice, also causing release of melanin into the extracellular space which could provide additional target for repeated treatments. Transient effects of RIT on WBC and platelet counts resolved by Day 14 post-treatment. EXPERIMENTAL DESIGN: Tris(2-Carboxyethyl) Phosphine Hydrochloride (TCEP) was evaluated as potential agent for generation of -SH groups on 6D2 mAb. TCEP-treated 6D2 mAb was radiolabeled with (188)Re and its radiochemical purity and stability was measured by ITLC and HPLC and its immunoreactivity--by melanin-binding ELISA. The pharmacokinetics, therapeutic efficacy and acute hematologic toxicity studies were performed in nude mice bearing lightly pigmented A2058 human metastatic melanoma tumors. CONCLUSIONS: We have developed radiolabeling and quality control procedures for melanin-binding (188)Re-6D2 mAb which made possible currently an on-going Phase I clinical trial in patients with metastatic melanoma.

Validation of the lower gastrointestinal electronic referral protocol.

BACKGROUND: Recognition of people presenting to the general practitioner with symptoms suggestive of colorectal cancer varies considerably, as do the subsequent patterns of referral and treatment. The Lower Gastrointestinal Electronic Referral Protocol (e-RP) was developed to be used alongside the national Choose and Book programme. This paper addresses the validation of the e-RP. METHODS: The e-RP was validated using three datasets: 100 consecutive patients with colorectal cancer, 100 2-week wait (TWW) suspected cancer referrals and 100 routine referrals. The actual destination of referred patients, their clinical diagnosis and referral urgency were compared with destination and referral urgency assigned by the e-RP. RESULTS: Some 43.0 per cent of patients with colorectal cancer were actually referred through the TWW system and the e-RP successfully upgraded 85.0 per cent of these patients as TWW referrals (Pearson chi(2) = 9.76, 1 d.f., P = 0.002). The e-RP also redirected three of four patients with colorectal cancer in routine referrals to TWW clinics. Right-sided cancers were appropriately directed to colonoscopy as the first contact in secondary care or to outpatients for investigation of a palpable mass. Most patients with left-sided cancers were directed to flexible sigmoidoscopy clinics. CONCLUSION: A dedicated referral protocol addressing all colorectal symptoms would significantly improve the overall yield of colorectal cancers through the TWW route and reduce delays in patient pathways with 'straight to test' in secondary care.

Inter general practice variability in use of referral guidelines for colorectal cancer.

OBJECTIVE: The Two-Week Wait (TWW) referral system for suspected colorectal cancers has a low yield. To examine this, we assessed the referral pattern of general practices within four primary care trusts and looked at the variability of yield of colorectal cancer amongst all TWW referrals and assessed the reasons for variability. METHOD: A prospectively collected database of all colorectal cancers was examined for new cases diagnosed in the 12 months from April 1st 2004. Patients were cross-referenced via general practitioner (GP) codes to identify the referral origin. Reasons for the variability in referral patterns from each general practice were assessed in relation to TWW referrals, population demographics and through postal questionnaire of GPs. RESULTS: A total of 175 patients diagnosed with colorectal cancer were referred from 49 general practices. Whilst there was a positive correlation between the number of TWW referrals and colorectal cancer per 1000-practice population (P = 0.001; Spearman correlation coefficient r(s=0.447,) two-tailed), there was a big discrepancy between referrals and cancer diagnosed in many general practices. Twenty-six general practices (53%) had no colorectal cancer diagnosed via the TWW route and these practices had significantly lower utilization of the TWW referral pathway. In the postal survey, 22% of GPs were unaware of TWW clinics or colorectal cancer referral guidelines and only 8% of GPs knew the number of referral criteria. CONCLUSION: This study demonstrates wide variability within primary care, in the appropriate use of colorectal cancer referral guidelines. General practices should be targeted for education.

Should we pursue patients who fail to attend colorectal clinics? A 9-year study.

INTRODUCTION: No uniform protocol exists on how to deal with patients who fail to attend colorectal clinics. Our aim was to identify whether the tendency to 'failure to attend' (FTA) in the colorectal clinic was associated with FTA in other clinics and also whether FTA patients have serious pathology. PATIENTS AND METHODS: This was a retrospective study of a prospectively recorded list of FTA patients, in colorectal urgent or two-week wait clinics from 1996-2004. RESULTS: A total of 151 patients, who failed to attend their first appointment, were included in the study. Of these, 61 (40.4%) were colorectal referrals, 76 (50.3%) were general surgical referrals, and for 14 (9.3%) case notes were not available. There were 59 FTA episodes in 61 colorectal patients associated with 59 FTA episodes in other clinics (Pearson correlation: r = 0.411; P = 0.01, two-tailed, SPSS v.12). Of 58 colorectal outcomes, five (8.6%) colorectal cancers (CRC) were diagnosed, 23 (39.6%) were persistent non-attendees, 16 (27.5%) had benign colorectal pathology, two (3.4%) benign non-colorectal outcomes and 12 (20.6%) normal outcomes. CONCLUSIONS: Tendency to FTA is habitual. Care needs to be exercised in the management of FTAs to avoid delayed presentation of colorectal cancer.

Trends in head and neck microvascular reconstructive surgery in Liverpool (1992-2001).

Microvascular reconstructive techniques in head and neck surgery are well established, but we are now entering an era of modification exemplified by perforator and free style free flaps. We present a review of the database introduced into the unit in 1992 over a 10-year period, during which time 977 patients with malignant disease were operated on and 620 defects were reconstructed with free flaps. There were 358 radial forearm flaps, 78 composite radial forearm flaps, 84 iliac crest flaps, 43 fibular flaps, 24 from the scapula, 26 from the latissimus dorsi, 4 from the rectus abdominis, and 3 from the lateral arm. The main changes over this time have been the use of more bulky flaps for larger resections of the tongue and the preference for iliac crest flaps over those from the fibula and forearm for composite reconstructions. Improving reliability of tissue transfer remains an important aim, and further development of reliable objective methods of monitoring of flaps is required.